CLEC12A and acute myeloid leukemia: This platform provides a promising therapeutic avenue to overcome current barriers in AML CAR T-cell development and improve patient outcomes.<h4>Significance</h4>Nanobody-based CLL-1 CAR T-cell therapy balances potent antitumor activity with hematopoietic preservation, highlighting the potential of our CLL-1 CAR T-cell platform as a next-generation, safer, and clinically superior strategy for effective AML treatment.